Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide

Dilip Unnikrishnan, Janice P. Dutcher, Nikita Varshneya, Richard J. Lucariello, Marietta Api, Susan Garl, Peter H. Wiernik, Salvatore Chiaramida

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Arsenic trioxide is used in clinical trials in the treatment of relapsed and resistant cases of acute promyelocytic leukemia. Adverse effects from arsenic in these studies have been multisystemic. Arsenic is known to cause corrected QT-interval prolongation and T-wave changes, but the potential for serious ventricular arrhythmias is less well understood. Torsades de pointes, a form of ventricular tachycardia, has been reported with arsenic poisoning but not at therapeutic doses used in protocols for hematologic malignancies. We describe 3 patients in whom this arrhythmia developed while they were treated with arsenic trioxide. Early recognition of the arrhythmia or correction of contributory factors is important because arsenic induced ventricular arrhythmias ere known to be resistant to most chemical methods and electrical cardioversion.

Original languageEnglish (US)
Pages (from-to)1514-1516
Number of pages3
JournalBlood
Volume97
Issue number5
DOIs
StatePublished - Mar 1 2001
Externally publishedYes

Fingerprint

Torsades de Pointes
Arsenic
Cardiac Arrhythmias
Leukemia
Arsenic Poisoning
Electric Countershock
Acute Promyelocytic Leukemia
Hematologic Neoplasms
Ventricular Tachycardia
Clinical Trials
arsenic trioxide
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Unnikrishnan, D., Dutcher, J. P., Varshneya, N., Lucariello, R. J., Api, M., Garl, S., ... Chiaramida, S. (2001). Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood, 97(5), 1514-1516. https://doi.org/10.1182/blood.V97.5.1514

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. / Unnikrishnan, Dilip; Dutcher, Janice P.; Varshneya, Nikita; Lucariello, Richard J.; Api, Marietta; Garl, Susan; Wiernik, Peter H.; Chiaramida, Salvatore.

In: Blood, Vol. 97, No. 5, 01.03.2001, p. 1514-1516.

Research output: Contribution to journalArticle

Unnikrishnan, D, Dutcher, JP, Varshneya, N, Lucariello, RJ, Api, M, Garl, S, Wiernik, PH & Chiaramida, S 2001, 'Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide', Blood, vol. 97, no. 5, pp. 1514-1516. https://doi.org/10.1182/blood.V97.5.1514
Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello RJ, Api M, Garl S et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood. 2001 Mar 1;97(5):1514-1516. https://doi.org/10.1182/blood.V97.5.1514
Unnikrishnan, Dilip ; Dutcher, Janice P. ; Varshneya, Nikita ; Lucariello, Richard J. ; Api, Marietta ; Garl, Susan ; Wiernik, Peter H. ; Chiaramida, Salvatore. / Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. In: Blood. 2001 ; Vol. 97, No. 5. pp. 1514-1516.
@article{71d7904a51554426b8fec56ece7dbd06,
title = "Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide",
abstract = "Arsenic trioxide is used in clinical trials in the treatment of relapsed and resistant cases of acute promyelocytic leukemia. Adverse effects from arsenic in these studies have been multisystemic. Arsenic is known to cause corrected QT-interval prolongation and T-wave changes, but the potential for serious ventricular arrhythmias is less well understood. Torsades de pointes, a form of ventricular tachycardia, has been reported with arsenic poisoning but not at therapeutic doses used in protocols for hematologic malignancies. We describe 3 patients in whom this arrhythmia developed while they were treated with arsenic trioxide. Early recognition of the arrhythmia or correction of contributory factors is important because arsenic induced ventricular arrhythmias ere known to be resistant to most chemical methods and electrical cardioversion.",
author = "Dilip Unnikrishnan and Dutcher, {Janice P.} and Nikita Varshneya and Lucariello, {Richard J.} and Marietta Api and Susan Garl and Wiernik, {Peter H.} and Salvatore Chiaramida",
year = "2001",
month = "3",
day = "1",
doi = "10.1182/blood.V97.5.1514",
language = "English (US)",
volume = "97",
pages = "1514--1516",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide

AU - Unnikrishnan, Dilip

AU - Dutcher, Janice P.

AU - Varshneya, Nikita

AU - Lucariello, Richard J.

AU - Api, Marietta

AU - Garl, Susan

AU - Wiernik, Peter H.

AU - Chiaramida, Salvatore

PY - 2001/3/1

Y1 - 2001/3/1

N2 - Arsenic trioxide is used in clinical trials in the treatment of relapsed and resistant cases of acute promyelocytic leukemia. Adverse effects from arsenic in these studies have been multisystemic. Arsenic is known to cause corrected QT-interval prolongation and T-wave changes, but the potential for serious ventricular arrhythmias is less well understood. Torsades de pointes, a form of ventricular tachycardia, has been reported with arsenic poisoning but not at therapeutic doses used in protocols for hematologic malignancies. We describe 3 patients in whom this arrhythmia developed while they were treated with arsenic trioxide. Early recognition of the arrhythmia or correction of contributory factors is important because arsenic induced ventricular arrhythmias ere known to be resistant to most chemical methods and electrical cardioversion.

AB - Arsenic trioxide is used in clinical trials in the treatment of relapsed and resistant cases of acute promyelocytic leukemia. Adverse effects from arsenic in these studies have been multisystemic. Arsenic is known to cause corrected QT-interval prolongation and T-wave changes, but the potential for serious ventricular arrhythmias is less well understood. Torsades de pointes, a form of ventricular tachycardia, has been reported with arsenic poisoning but not at therapeutic doses used in protocols for hematologic malignancies. We describe 3 patients in whom this arrhythmia developed while they were treated with arsenic trioxide. Early recognition of the arrhythmia or correction of contributory factors is important because arsenic induced ventricular arrhythmias ere known to be resistant to most chemical methods and electrical cardioversion.

UR - http://www.scopus.com/inward/record.url?scp=0035283137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035283137&partnerID=8YFLogxK

U2 - 10.1182/blood.V97.5.1514

DO - 10.1182/blood.V97.5.1514

M3 - Article

C2 - 11222403

AN - SCOPUS:0035283137

VL - 97

SP - 1514

EP - 1516

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -